Sartorius AGSUVPF -15.40%85 EV-to-FCF is 41.78 as of Jun. 28, 2026, which is 58% below its 10-year median of 98.81. GuruFocus rates SUVPF with a GF Score™ of 85/100 and a GF Value™ of $268.44 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 419 Medical Devices & Instruments companies, Sartorius AG ranks worse than 71.6% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sartorius AG's Enterprise Value is $21,577 Mil.
Sartorius AG's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $516 Mil. Therefore, Sartorius AG's EV-to-FCF for today is 41.78.
The historical rank and industry rank for Sartorius AG's EV-to-FCF or its related term are showing as below:
SUVPF'
s EV-to-FCF Range Over the Past 10 Years
Min: -88.19 Med: 98.81 Max: 917.31
Current: 42.8
During the past 13 years, the highest EV-to-FCF of Sartorius AG was 917.31. The lowest was -88.19. And the median was 98.81.
SUVPF's EV-to-FCF is ranked worse than 71.6% of 419
companies
in the Medical Devices & Instruments industry
Industry Median: 22.67
vs SUVPF: 42.80
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sartorius AG's PE Ratio (TTM) for today is calculated as:
Sartorius AG's share price for today is $243.82.
Sartorius AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.797.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sartorius AG EV-to-FCF Related Terms
Sartorius AG EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Sartorius AG's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Sartorius AG's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius AG EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Sartorius AG's EV-to-FCF falls into.
Sartorius AG's current Enterprise Value is $21,577 Mil.
Sartorius AG's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $516 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius AG (SUVPF) has a EV-to-FCF of 41.78 as of Jun. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sartorius AG and its competitors. This is 58% below median its historical median of 98.81. According to the industry distribution chart, Sartorius AG ranks #300 out of 419 companies in the Medical Devices & Instruments industry, placing it in the top 71.6%.
Is Sartorius AG's EV-to-FCF too high?
Sartorius AG's current EV-to-FCF of 41.78 is 58% below median its 10-year median of 98.81. The Medical Devices & Instruments industry median EV-to-FCF is 22.67. Sartorius AG's value of 41.78 is 84.3% above this industry median. Based on the distribution chart, Sartorius AG ranks #300 out of 419 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Sartorius AG has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius AG's EV-to-FCF compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius AG ranks #300 out of 419 companies for EV-to-FCF. This places Sartorius AG in the lower half of its industry. The industry median EV-to-FCF is 22.67. Sartorius AG's value of 41.78 is 84.3% above this benchmark. While the company's 10-year median is 98.81 vs. the industry median of 22.67, Sartorius AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.67, based on 419 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius AG's current EV-to-FCF of 41.78 is 84.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sartorius AG and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius AG's current EV-to-FCF is 41.78, which is 58% below median its own 10-year median of 98.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius AG stock overvalued right now?
Based on GuruFocus' analysis, Sartorius AG (SUVPF) is currently considered Modestly Undervalued. The stock's GF Value™ is $268.44, compared to a current price of $243.82 — trading 9.2% below its estimated fair value. The current EV-to-FCF is 41.78, which is 58% below median its 10-year median of 98.81 and 84.3% above the Medical Devices & Instruments industry median of 22.67. Sartorius AG's overall GF Score™ is 85/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Sartorius AG (SUVPF), the current EV-to-FCF is 41.78 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius AG (SUVPF) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued.
The current stock price of $243.82 is trading 9.2% below its estimated GF Value™ of $268.44.
GuruFocus considers Sartorius AG to be Modestly Undervalued.
Key valuation signals for SUVPF:
EV-to-FCF: 41.78 (58% below median its 10-year median of 98.81)
GF Value™: $268.44 vs. price of $243.82 (9.2% below fair value)
Industry Position: 84.3% above the Medical Devices & Instruments median (#300 of 419)
No single metric tells the full story. See the SUVPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
85GF Score
Get the complete analysis for SUVPF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SUVPF has been successfully added to your 
